» Articles » PMID: 31004154

Lung Cancer Survival and Comorbidities in Lung Cancer Screening Participants of the Gdańsk Screening Cohort

Overview
Specialty Public Health
Date 2019 Apr 21
PMID 31004154
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In 2010, the World Health Organisation recommended implementation of screening programmes in four groups of diseases-neoplasms, cardiovascular diseases (CVD), diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD). It is due to the fact that they share the same, modifiable risk factors.

Methods: Between 2009 and 2011, 8637 heavy smokers (aged 50-75, smoking history >20 pack-years) were screened in the Pomeranian Pilot Lung Cancer Screening Programme (PPP) in Gdańsk, Poland. We looked at 5-year follow-up and analysed the medical events and comorbidities of all participants. One health care provider in the Polish health care system provides a unique opportunity to gather most reliable data on all medical events in each person.

Results: In 52.0% of lung cancer screening participants CVD (33.5%), DM (26.0%) and COPD (21.0%) were diagnosed. Prevalence of these diseases is higher in lung cancer patients than in the non-cancer screening group (P < 0.0001). One hundred and seven (1.2%) lung cancers were diagnosed during PPP programme performance and another 382 cases (4.4%) in the 5-year follow-up, so the potential mean annual lung cancer detection rate is 0.77%.

Conclusions: Lung cancer screening programme offers a great potential for joint screening of lung cancer, CVD, diabetes and COPD.

Citing Articles

Evaluation of Conventional Cardiovascular Risk Factors and Ordinal Coronary Artery Calcium Scoring in a Lung Cancer Screening Cohort.

Kasprzyk P, Undrunas A, Dziadziuszko K, Dziedzic R, Kuziemski K, Szurowska E J Cardiovasc Dev Dis. 2024; 11(1).

PMID: 38248886 PMC: 10816916. DOI: 10.3390/jcdd11010016.


The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.

Almatrafi A, Thomas O, Callister M, Gabe R, Beeken R, Neal R J Med Screen. 2022; 30(1):3-13.

PMID: 35942779 PMC: 9925896. DOI: 10.1177/09691413221117685.


Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians.

Criner G, Agusti A, Borghaei H, Friedberg J, Martinez F, Miyamoto C Chronic Obstr Pulm Dis. 2022; 9(3):454-476.

PMID: 35790131 PMC: 9448004. DOI: 10.15326/jcopdf.2022.0296.


Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study.

Nance M, Khazi Z, Kaifi J, Avella D, Alnijoumi M, Davis R J Clin Imaging Sci. 2021; 11:7.

PMID: 33654576 PMC: 7911126. DOI: 10.25259/JCIS_224_2020.


Analysis of lung cancer risk model (PLCO and LLP) performance in a community-based lung cancer screening programme.

Lebrett M, Balata H, Evison M, Colligan D, Duerden R, Elton P Thorax. 2020; 75(8):661-668.

PMID: 32631933 PMC: 7402560. DOI: 10.1136/thoraxjnl-2020-214626.